Legumain: a potential biomarker for atherosclerosis
Journal of Pharmacy and Pharmacology · 2023
DOI: 10.1093/jpp/rgad073 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Pharmacy and Pharmacology, 2023. Verfasst von Bo-Yi Ke und 3 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Pharmacy and Pharmacology, School of Pharmaceutical Sciences, University of South China, Hengyang 421001, China. Hauptthemen laut MEDLINE: Asparagine, Atherosclerosis. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 84 Literaturangaben. Gefördert von: Scientific Research Project of Hunan Provincial Department of Education, Project of Hunan Provincial Health Committee, National Education Ministry College Student Innovation and Entrepreneurship Training Program Project.
Abstract (Originalsprache)
Atherosclerosis is a lipid-driven chronic inflammatory disease that poses a serious threat to health. Legumain (LGMN), also known as asparagine endonuclease, is a new type of cysteine proteases that can specifically hydrolyze substrate molecules containing asparagine residues. It has anti-apoptotic effects in mammals and plays an antigen-presenting role in inflammatory response. Several studies have found that LGMN can activate multiple signal pathways to promote cell apoptosis and migration, inflammatory response, and the development of atherosclerosis. Importantly, LGMN exerts pro-atherogenic effects by participating in a variety of pathophysiological mechanisms of atherosclerosis, including vascular remodeling, inflammatory response, plaque stability, and the degradation of extracellular matrix. In the present review, we describe the LGMN distribution, structure, generation, and functional partners. Furthermore, we summarize the relationship between LGMN and atherosclerosis. Based on the relationship between LGMN and atherosclerosis, LGMN may be a potential biomarker for atherosclerosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Pharmacy and Pharmacology, School of Pharmaceutical Sciences, University of South China, Hengyang 421001, China.
- Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study, University of South China, Hengyang 421001, China.
- Department of Laboratory Medicine, Liuzhou People's Hospital, Liuzhou 545006, China.
ORCID-Profile: Shu-Zhi Wang
Förderung
- Scientific Research Project of Hunan Provincial Department of Education
- Project of Hunan Provincial Health Committee
- National Education Ministry College Student Innovation and Entrepreneurship Training Program Project
Zitieren
APA
Ke, B. Y., Qin, Y. S., Cheng, L., & Wang, S. Z. (2023). Legumain: a potential biomarker for atherosclerosis. Journal of Pharmacy and Pharmacology. https://doi.org/10.1093/jpp/rgad073
Vancouver
Ke BY, Qin YS, Cheng L, Wang SZ. Legumain: a potential biomarker for atherosclerosis. Journal of Pharmacy and Pharmacology. 2023. doi:10.1093/jpp/rgad073
BibTeX
@article{Ke2023,
author = {Ke, Bo-Yi and Qin, Yu-Sheng and Cheng, Lu and Wang, Shu-Zhi},
title = {Legumain: a potential biomarker for atherosclerosis},
journal = {Journal of Pharmacy and Pharmacology},
year = {2023},
doi = {10.1093/jpp/rgad073}
}
EUVIMED